Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
Sanofi-Aventis (SNY)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
4 new
Instablogs
1 new
StockTalks
2 new
Sentiment
Comments
13 new
News & PR
Market Currents
Buzz
Twitter: SNY
Coverage
Top Authors
Cramer
1 new
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
Analysis - Latest Articles
by
most recent
|
most commented
Equities Update: Broad Market Gains
Dec 21
•
Midnight Trader
•
1 Comment
Sanofi-Aventis Acquires Chattem in $1.9 Billion Cash Deal
Dec 21
•
optionMONSTER
•
Comment!
Sanofi-Aventis Going OTC with Chattem Buy
Dec 21
•
EP Vantage
•
3 Comments
Wall Street Breakfast: Must-Know News
Dec 21
•
SA Editor Eli Hoffmann
•
9 Comments
This Week's Failed Trials, Missed Targets in Biotech
Dec 20
•
The Burrill Report
•
1 Comment
China Biotech Week in Review: Deals and CRO News
Dec 14
•
ChinaBio Today
•
1 Comment
Making and Breaking Biotech Deals
Dec 14
•
The Burrill Report
•
Comment!
H1N1: What It Means for Pharma
Dec 2
•
R. Scott Raynovich
•
2 Comments
Immunogen's Busy Month, Part II
Dec 2
•
Ohad Hammer
•
Comment!
Immunogen's Busy Month, Part I
Dec 1
•
Ohad Hammer
•
Comment!
Health Care Takes Bigger Slice of Risk Capital
Nov 30
•
Sydney Williams
•
Comment!
8 HealthCare Stocks with 3%+ Dividends
Nov 29
•
Hao Jin
•
9 Comments
Sanofi Expands Regeneron Agreement
Nov 26
•
Zacks.com
•
Comment!
Competition in Blood - Thinners: Win - Win for Everyone Involved
Nov 20
•
Derek Lowe
•
Comment!
AOB's Cash Generation Provides Backstop to Earnings Miss
Nov 17
•
Jeffrey Walkenhorst
•
3 Comments
Analyze Earnings Yield Like Warren Buffett
Nov 17
•
YCHARTS.com
•
1 Comment
Sanofi-Aventis to Establish Venture Capital Fund, Looking for 'Right Brain Activity'
Nov 15
•
The Burrill Report
•
Comment!
Big Pharma Willing to Pay for Biotech Innovation
Nov 15
•
The Burrill Report
•
Comment!
The Complete List of French ADR Stocks
Nov 9
•
David Hunkar
•
2 Comments
D.C. Vaccine Conference: Why Investors Should Stay Tuned
Nov 9
•
M. E. Garza
•
Comment!
EFA: Diversify Your Portfolio Outside the U.S.
Nov 8
•
Hao Jin
•
4 Comments
A 130 / 30 Global Pharma Strategy
Nov 5
•
Mike Havrilla
•
2 Comments
China Biotech Week in Review: Is CRO Consolidation a New Theme?
Nov 1
•
ChinaBio Today
•
1 Comment
This Week in Biotech: More Treats than Tricks
Nov 1
•
The Burrill Report
•
Comment!
Healthcare Profits: Assessing Company Sensitivity to Obamacare
Oct 30
•
Richard Shaw
•
11 Comments
Unilife: Medical Device Innovator Creating Jobs in Pennsylvania
Oct 30
•
Mike Havrilla
•
2 Comments
Stock Screener: 10 Foreign Stocks with Caps Above $100B, Yields Above 3%
Oct 29
•
David Hunkar
•
Comment!
Sanofi-Aventis's New JV Will Provide Entry into China’s OTC Market
Oct 27
•
ChinaBio Today
•
Comment!
Wall Street Breakfast: Must-Know News
Oct 23
•
SA Editor Eli Hoffmann
•
19 Comments
Tough Decisions for Antigenics
Oct 22
•
EP Vantage
•
3 Comments
China Biotech Week in Review: A Multitude of Deals and Collaborations
Oct 18
•
ChinaBio Today
•
1 Comment
Biotech: Q3 Market Update
Oct 16
•
R. Scott Raynovich
•
1 Comment
Dow 10k: The Higher They Rise, The Harder They Fall
Oct 15
•
Matthew Rafat
•
20 Comments
Sanofi-Aventis Animal Health Division Starts China Facility Expansion
Oct 13
•
ChinaBio Today
•
Comment!
OncoGenex: Room for Further Growth?
Oct 8
•
EP Vantage
•
Comment!
H1N1: How to Buy into the Fear
Oct 7
•
Jim Van Meerten
•
1 Comment
Sanofi-Aventis Boosts Pipeline with In-Licensing Deals, Acqusitions
Oct 6
•
Zacks.com
•
Comment!
Capital Markets Open Up to Biotechs
Oct 4
•
The Burrill Report
•
Comment!
Healthcare Takeover Talk Continues
Sep 30
•
M. E. Garza
•
8 Comments
Analyzing the Oracle: Berkshire Hathaway Holdings and Analysis
Sep 29
•
Value Expectations
•
2 Comments
Glaxo Could Find Reasons to Extend Its Alliance with Dr. Reddy's
Sep 22
•
EP Vantage
•
2 Comments
1
2
3
4
5
6
7
Next Page